Bristol Myers Squibb faces identity crisis as CEO Chris Boerner enters make-or-break year

Bristol Myers Squibb is at a strategic crossroads as its chief executive, Chris Boerner, approaches the midway point of his tenure.

After roughly two and a half years in the role, Boerner has overseen a period marked by uncertainty about the company's direction and identity.

Analysts view the coming year as critical for the firm to clarify its focus and deliver results that will determine its long term trajectory.